2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
David M. Gershenson, MD, discusses the results of the phase 3 MILO trial in low-grade serous ovarian cancer.
David M. Gershenson, MD, professor of gynecologic oncology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the results of the phase 3 MILO trial (NCT01849874) in low-grade serous ovarian cancer.
The randomized MILO trial demonstrated a 24% response rate with binimetinib (Mektovi) in patients with low-grade serous ovarian cancer, Gershenson says. The study was closed prematurely because the HR for progression-free survival (PFS) crossed the predetermined futility boundary, therefore failing to meet the primary end point of the study.
Notably, findings from a post-hoc exploratory analysis of the study showed that patients with recurrent low-grade serous ovarian cancer who harbored a KRAS mutation were 3.4 times more likely to have a complete or partial radiographic response to treatment with binimetinib compared with patients who had KRAS wild-type disease. A similar trend was observed for patients harboring any MAPK mutations, Gershenson concludes.